FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169031812> ?p ?o ?g. }

• W2169031812 endingPage "974" @default.
• W2169031812 startingPage "966" @default.
• W2169031812 abstract "Background Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab—a chimeric monoclonal antibody against interleukin 6—in HIV-negative patients with multicentric Castleman's disease. Methods We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwide. We enrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman's disease. Treatment allocation was randomised with a computer-generated list, with block size six, and stratification by baseline corticosteroid use. Patients and investigators were masked to treatment allocation. Patients were randomly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all patients also received best supportive care. Patients continued treatment until treatment failure. The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-to-treat population. Enrolment has been completed. The study is registered with ClinicalTrials.gov, number NCT01024036. Findings We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 34·0%, 95% CI 11·1–54·8, p=0·0012). The incidence of grade 3 or more adverse events (25 [47%] vs 14 [54%]) and serious adverse events (12 [23%] vs five [19%]) was similar in each group despite longer median treatment duration with siltuximab than with placebo (375 days [range 1–1031] vs 152 days [23–666]). The most common grade 3 or higher were fatigue (five vs one), night sweats (four vs one), and anaemia (one vs three). Three (6%) of 53 patients had serious adverse events judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, sepsis). Interpretation Siltuximab plus best supportive care was superior to best supportive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged exposure. Siltuximab is an important new treatment option for this disease. Funding Janssen Research & Development. Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab—a chimeric monoclonal antibody against interleukin 6—in HIV-negative patients with multicentric Castleman's disease. We did this randomised, double-blind, placebo-controlled study at 38 hospitals in 19 countries worldwide. We enrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman's disease. Treatment allocation was randomised with a computer-generated list, with block size six, and stratification by baseline corticosteroid use. Patients and investigators were masked to treatment allocation. Patients were randomly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all patients also received best supportive care. Patients continued treatment until treatment failure. The primary endpoint was durable tumour and symptomatic response for at least 18 weeks for the intention-to-treat population. Enrolment has been completed. The study is registered with ClinicalTrials.gov, number NCT01024036. We screened 140 patients, 79 of whom were randomly assigned to siltuximab (n=53) or placebo (n=26). Durable tumour and symptomatic responses occurred in 18 (34%) of 53 patients in the siltuximab group and none of 26 in the placebo group (difference 34·0%, 95% CI 11·1–54·8, p=0·0012). The incidence of grade 3 or more adverse events (25 [47%] vs 14 [54%]) and serious adverse events (12 [23%] vs five [19%]) was similar in each group despite longer median treatment duration with siltuximab than with placebo (375 days [range 1–1031] vs 152 days [23–666]). The most common grade 3 or higher were fatigue (five vs one), night sweats (four vs one), and anaemia (one vs three). Three (6%) of 53 patients had serious adverse events judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, sepsis). Siltuximab plus best supportive care was superior to best supportive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged exposure. Siltuximab is an important new treatment option for this disease." @default.
• W2169031812 created "2016-06-24" @default.
• W2169031812 creator A5017226768 @default.
• W2169031812 creator A5026973682 @default.
• W2169031812 creator A5027190055 @default.
• W2169031812 creator A5027220663 @default.
• W2169031812 creator A5028165330 @default.
• W2169031812 creator A5030040961 @default.
• W2169031812 creator A5038243788 @default.
• W2169031812 creator A5045740077 @default.
• W2169031812 creator A5047257257 @default.
• W2169031812 creator A5048903346 @default.
• W2169031812 creator A5049970120 @default.
• W2169031812 creator A5052719640 @default.
• W2169031812 creator A5054343933 @default.
• W2169031812 creator A5055817555 @default.
• W2169031812 creator A5057231642 @default.
• W2169031812 creator A5062101208 @default.
• W2169031812 creator A5066583406 @default.
• W2169031812 creator A5069409328 @default.
• W2169031812 creator A5069563388 @default.
• W2169031812 creator A5077970092 @default.
• W2169031812 creator A5085370688 @default.
• W2169031812 creator A5090044223 @default.
• W2169031812 date "2014-08-01" @default.
• W2169031812 modified "2023-10-12" @default.
• W2169031812 title "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial" @default.
• W2169031812 cites W1987091861 @default.
• W2169031812 cites W2024170931 @default.
• W2169031812 cites W2039067114 @default.
• W2169031812 cites W2041030605 @default.
• W2169031812 cites W2041038922 @default.
• W2169031812 cites W2043121958 @default.
• W2169031812 cites W2044588509 @default.
• W2169031812 cites W2046516518 @default.
• W2169031812 cites W2051544229 @default.
• W2169031812 cites W2064355488 @default.
• W2169031812 cites W2067046746 @default.
• W2169031812 cites W2073910573 @default.
• W2169031812 cites W2092354459 @default.
• W2169031812 cites W2112605252 @default.
• W2169031812 cites W2132160266 @default.
• W2169031812 cites W2133201432 @default.
• W2169031812 cites W2144817522 @default.
• W2169031812 cites W2171799063 @default.
• W2169031812 cites W2565971937 @default.
• W2169031812 cites W63130883 @default.
• W2169031812 cites W94647491 @default.
• W2169031812 doi "https://doi.org/10.1016/s1470-2045(14)70319-5" @default.
• W2169031812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25042199" @default.
• W2169031812 hasPublicationYear "2014" @default.
• W2169031812 type Work @default.
• W2169031812 sameAs 2169031812 @default.
• W2169031812 citedByCount "324" @default.
• W2169031812 countsByYear W21690318122014 @default.
• W2169031812 countsByYear W21690318122015 @default.
• W2169031812 countsByYear W21690318122016 @default.
• W2169031812 countsByYear W21690318122017 @default.
• W2169031812 countsByYear W21690318122018 @default.
• W2169031812 countsByYear W21690318122019 @default.
• W2169031812 countsByYear W21690318122020 @default.
• W2169031812 countsByYear W21690318122021 @default.
• W2169031812 countsByYear W21690318122022 @default.
• W2169031812 countsByYear W21690318122023 @default.
• W2169031812 crossrefType "journal-article" @default.
• W2169031812 hasAuthorship W2169031812A5017226768 @default.
• W2169031812 hasAuthorship W2169031812A5026973682 @default.
• W2169031812 hasAuthorship W2169031812A5027190055 @default.
• W2169031812 hasAuthorship W2169031812A5027220663 @default.
• W2169031812 hasAuthorship W2169031812A5028165330 @default.
• W2169031812 hasAuthorship W2169031812A5030040961 @default.
• W2169031812 hasAuthorship W2169031812A5038243788 @default.
• W2169031812 hasAuthorship W2169031812A5045740077 @default.
• W2169031812 hasAuthorship W2169031812A5047257257 @default.
• W2169031812 hasAuthorship W2169031812A5048903346 @default.
• W2169031812 hasAuthorship W2169031812A5049970120 @default.
• W2169031812 hasAuthorship W2169031812A5052719640 @default.
• W2169031812 hasAuthorship W2169031812A5054343933 @default.
• W2169031812 hasAuthorship W2169031812A5055817555 @default.
• W2169031812 hasAuthorship W2169031812A5057231642 @default.
• W2169031812 hasAuthorship W2169031812A5062101208 @default.
• W2169031812 hasAuthorship W2169031812A5066583406 @default.
• W2169031812 hasAuthorship W2169031812A5069409328 @default.
• W2169031812 hasAuthorship W2169031812A5069563388 @default.
• W2169031812 hasAuthorship W2169031812A5077970092 @default.
• W2169031812 hasAuthorship W2169031812A5085370688 @default.
• W2169031812 hasAuthorship W2169031812A5090044223 @default.
• W2169031812 hasConcept C126322002 @default.
• W2169031812 hasConcept C141071460 @default.
• W2169031812 hasConcept C142724271 @default.
• W2169031812 hasConcept C168563851 @default.
• W2169031812 hasConcept C197934379 @default.
• W2169031812 hasConcept C203092338 @default.
• W2169031812 hasConcept C204787440 @default.
• W2169031812 hasConcept C27081682 @default.
• W2169031812 hasConcept C2908647359 @default.
• W2169031812 hasConcept C71924100 @default.
• W2169031812 hasConcept C90924648 @default.

• next